GenSight Biologics announces the drawdown of the first EUR 8 million tranche under its credit agreement with the European Investment Bank

GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update

GenSight Biologics to Present REFLECT Phase III Data with LUMEVOQ® at the NANOS 2022 Meeting